Physician profile
Jeffrey C Laurence
NPI 1720175805
$639,924.74
in general payments reported to CMS, 2019-2025
11 companies · $110K in 2025
The $110K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $27K · 2021: $655 · 2022: $127K · 2023: $170K · 2024: $195K · 2025: $110K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $279K · Consulting Fee: $131K · Travel and Lodging: $58K · Food and Beverage: $7,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $278,740.04 |
| Consulting Fee | $131,010.93 |
| Travel and Lodging | $57,500.30 |
| Food and Beverage | $7,494.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $503,624.57 | 2019-2025 | Ultomiris, Soliris |
| Genzyme Corporation | $101,714.61 | 2023-2025 | |
| Omeros Corporation | $17,117.06 | 2019-2020 | |
| Samsung Bioepis Co., Ltd. | $4,902.34 | 2024 | |
| Bioverativ Therapeutics INC. | $4,298.25 | 2019 | |
| Jazz Pharmaceuticals INC. | $3,924.36 | 2019-2023 | Defitelio |
| Novartis Pharmaceuticals Corporation | $2,070.00 | 2025 | |
| Amgen INC. | $1,932.00 | 2020 | |
| Regeneron Pharmaceuticals, INC. | $140.00 | 2019 | |
| Rigel Pharmaceuticals, INC. | $138.08 | 2019 | |
| Pfizer INC. | $63.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Laurence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.